



Additional file 9. Clinical impact of several subsets of intraepithelial T cells in the total group of VSCC and in HPVnegVSCC patients only. Kaplan-Meier curves showing overall survival (left) and the recurrence free period (RFP; right) for VSCC patients with high (in red) and low (in blue) numbers of intraepithelial CD3⁺CD8⁺Foxp3⁻ (a) and intraepithelial CD3⁺CD8⁻Foxp3⁺ cells/mm² (b).

Moreover, we calculated the impact of T-cell phenotypes on HPVnegVSCC only (n=42, c-g) on clinical outcome. This showed that intraepithelial CD3⁺ (c), CD3⁺CD8⁻Foxp3⁺ T cells (d) retained their positive association with OS and RFP. While other phenotypes in HPVnegVSCC (e-g) were not associated with better clinical outcome.

Patients were grouped into the high or low groups based on the best cut-off value for each subset as determined by receiver operating characteristics (ROC) curve analysis. Cut-off values for the total cohort and HPVnegVSCC were similar (CD3⁺ cells were 309.4 cells/mm² and 192.7 cells/mm² for OS and RFP, respectively). The value of cells/mm² were for CD3⁺CD8⁺Foxp3⁻ cells 35.63 (OS) and 37.96 (RFP), for CD3⁺CD8⁻Foxp3⁺ cells 82.58 (OS) and 61.82 (RFP), for CD3⁺CD8⁺Foxp3⁻ cells 35.63 (OS) and 37.96 (RFP), for CD3⁺CD8⁻Foxp3⁺ cells 54.58 (OS) and 38.71 (RFP), and for CD3⁺PD1⁺ 37.67 (OS) and 99.96 (RFP). Patients with a T cell count below the cut-off value were classified as low, the others as high. A log-rank test was performed to calculate the difference in OS and RFP. Statistical significance of the survival distribution was analyzed by log-rank testing and differences were considered significant when p<0.05, as indicated with an asterisk (*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001).